Holen Sie sich die Stockscreener-App
17.15
1.42%
0.24
Handel nachbörslich:
17.13
-0.02
-0.12%
Schlusskurs vom Vortag:
$16.91
Offen:
$16.89
24-Stunden-Volumen:
416.11K
Relative Volume:
1.09
Marktkapitalisierung:
$6.07B
Einnahmen:
$4.89B
Nettoeinkommen (Verlust:
$-263.00M
KGV:
-22.17
EPS:
-0.7734
Netto-Cashflow:
$-167.84M
1W Leistung:
+5.80%
1M Leistung:
-0.35%
6M Leistung:
+25.73%
1J Leistung:
+5.60%
1-Tages-Spanne:
$16.89
$17.45
1-Wochen-Bereich:
$16.17
$17.45
52-Wochen-Spanne:
$10.45
$17.86
Bausch Lomb Corp Stock (BLCO) Company Profile
Firmenname
Bausch Lomb Corp
Sektor
Telefon
908-541-5456
Adresse
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, ALC, RMD, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
17.15 | 5.99B | 4.89B | -263.00M | -167.84M | -0.7734 |
|
ISRG
Intuitive Surgical Inc
|
495.15 | 175.02B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
171.68 | 59.03B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
80.48 | 38.53B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
263.54 | 40.20B | 5.40B | 1.49B | 1.78B | 10.12 |
|
MDLN
Medline Inc
|
45.29 | 39.42B | 27.43B | 1.27B | 1.01B | 1.5829 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | Eingeleitet | Goldman | Neutral |
| 2025-05-02 | Bestätigt | H.C. Wainwright | Buy |
| 2025-03-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-07-10 | Eingeleitet | Raymond James | Outperform |
| 2024-05-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-12 | Eingeleitet | Stifel | Hold |
| 2023-10-03 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-09 | Eingeleitet | Needham | Hold |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-06-24 | Eingeleitet | Evercore ISI | Outperform |
| 2022-06-06 | Eingeleitet | Citigroup | Buy |
| 2022-05-31 | Eingeleitet | Deutsche Bank | Hold |
| 2022-05-31 | Eingeleitet | Goldman | Neutral |
| 2022-05-31 | Eingeleitet | Guggenheim | Buy |
| 2022-05-31 | Eingeleitet | JP Morgan | Neutral |
| 2022-05-31 | Eingeleitet | Jefferies | Buy |
| 2022-05-31 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-05-11 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Bausch Lomb Corp Aktie (BLCO) Neueste Nachrichten
Nicox : Présentation des données des études de Phase 3 de NCX 470 au congrès annuel 2026 de l’American Glaucoma Society (AGS) - GlobeNewswire Inc.
3 Reasons to Sell BLCO and 1 Stock to Buy Instead - Finviz
Bausch + Lomb (NYSE:BLCO) Seems To Be Using A Lot Of Debt - 富途牛牛
Bausch + Lomb (NYSE:BLCO) Shares Down 0.9%What's Next? - MarketBeat
Published on: 2026-02-02 10:13:14 - baoquankhu1.vn
Bausch + Lomb Likely to Report a Q4 Beat on FX Tailwinds, Robust Performance of Eye Disease Portfolio, RBC Says - marketscreener.com
RBC Capital Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Raises Target Price to $21 - 富途牛牛
Bausch & Lomb stock price target raised to $21 from $19 at RBC Capital - Investing.com India
Bausch & Lomb stock price target raised to $21 from $19 at RBC Capital By Investing.com - Investing.com South Africa
Bausch Health stock unchanged as Phase 3 RED-C trial fails primary endpoint - Investing.com India
Bausch + Lomb Corp: Eyes On The Numbers As BLCO Tests Investor Patience - AD HOC NEWS
Growth Value: Is MLPR attractive for institutional investorsQuarterly Earnings Report & Proven Capital Preservation Tips - baoquankhu1.vn
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18 - BioSpace
Press Release: Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18 - 富途资讯
Stifel reiterates Hold rating on Bausch & Lomb stock amid competition concerns By Investing.com - Investing.com Nigeria
Stifel reiterates Hold rating on Bausch & Lomb stock amid competition concerns - Investing.com Nigeria
Bausch + Lomb Corporation (NYSE:BLCO) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Aug Patterns: Will Bausch Lomb Corporation outperform its industry peersJuly 2025 Earnings & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Bausch + Lomb Corporation (BLCO) Stock Analysis: Navigating Growth in the Healthcare Sector - DirectorsTalk Interviews
Goldman Sachs Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $19 - 富途牛牛
Intraocular Lens Market Size to Reach USD 9.85 Billion by 2033, Growing at a CAGR of 6.48% - GlobeNewswire Inc.
Published on: 2026-01-09 11:41:10 - Улправда
Will Bausch + Lomb Corporation (S2L) stock benefit from Fed rate cutsProduct Launch & Safe Entry Momentum Tips - ulpravda.ru
Bausch + Lomb (NYSE:BLCO) Rating Lowered to "Hold" at Evercore ISI - MarketBeat
Bausch + Lomb (NYSE:BLCO) Valuation Check After Mixed 90 Day And 1 Year Shareholder Returns - Yahoo Finance
Evercore Downgrades Bausch + Lomb Corp.(BLCO.US) to Hold Rating, Cuts Target Price to $18 - 富途牛牛
Bausch + Lomb Corporation (BLCO): Investor Outlook on Growth Potential and Strategic Positioning - DirectorsTalk Interviews
Glaucoma stories and research drive new Bausch + Lomb awareness push - Stock Titan
Bausch & Lomb CorpEnters fourth amendment to credit agreement dated as of May 10, 2022SEC filing - marketscreener.com
Bausch + Lomb just refinanced $2.8B in debt to cut interest margin - Stock Titan
Bausch + Lomb Signs Fourth Amendment to Credit Agreement With JPMorgan Chase and Lenders - TradingView — Track All Markets
Bausch + Lomb refinances term loans, extends maturities - TipRanks
Bausch + Lomb (BLCO): Investor Outlook on a Visionary Healthcare Player with a Focused Growth Trajectory - DirectorsTalk Interviews
Does Bausch + Lomb’s Rising Focus on Eye Health Make Its Current Share Price Attractive? - simplywall.st
Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Top eye-care leaders to speak at J.P. Morgan's big healthcare event - Stock Titan
[8-K/A] Bausch & Lomb Corp Amends Material Event Report | BLCO SEC FilingForm 8-K/A - Stock Titan
Bausch + Lomb Makes Key Appointments to Board of Directors - VisionMonday.com
Bausch + Lomb Corporation (NYSE:BLCO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Will Bausch + Lomb Corporation stock keep outperforming rivalsMarket Trend Summary & Reliable Breakout Forecasts - Улправда
Published on: 2025-12-18 17:17:15 - Улправда
Icahn Money Manager Sues His Bosses and Bausch + Lomb Over Anti-White Bias - Insurance Journal
Fund Exits $6.6 Million Bausch + Lomb Stake as Shares Lag by 9% This Past Year - The Globe and Mail
Bausch + Lomb Announces Refinancing of Outstanding Term B Loans - VisionMonday.com
Bausch + Lomb appoints two new directors to board effective January - Investing.com
Bausch + Lomb Adds New Directors to Board - TipRanks
Bausch & Lomb Corp Announces Board Appointments - TradingView — Track All Markets
Bausch + Lomb appoints two new directors to board effective January By Investing.com - Investing.com South Africa
Bausch + Lomb (NYSE: BLCO) appoints Eduardo Alfonso and Steven Collis to board - Stock Titan
Bausch + Lomb Brief: Appointing Eduardo C. Alfonso, and Steven H. Collis To Its Board, Effective Jan. 1, 2026; Board Will Then Be Comprised of 10 Directors - marketscreener.com
Finanzdaten der Bausch Lomb Corp-Aktie (BLCO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):